文献速递艾滋病与性传播感染

免疫营养在晚期人类免疫缺陷病毒感染中的作用:一项随机安慰剂对照临床试验(Promaltia研究)

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study).
PubMed 文献 · Clin Infect Dis · 2019-01-01

这项先导性多中心随机、安慰剂对照、双盲研究纳入78例未开始抗反转录病毒治疗(ART)且CD4 T细胞<350个/μL或艾滋病的HIV感染者,随机接受每日PMT25341(合生元、ω-3/6脂肪酸和氨基酸混合物)或安慰剂48周,均联合一线ART。主要终点CD4 T细胞计数变化(278 vs 250 cells/μL,P=.474)和CD4/CD8比值变化(0.30 vs 0.32,P=.854)在两组间无显著差异,次要终点亦无差异。

要点

  • PMT25341耐受良好,无归因于干预的3-4级不良事件。
  • PMT25341组与安慰剂组CD4 T细胞计数变化无显著差异(278 vs 250 cells/μL,P=.474)。
  • PMT25341组与安慰剂组CD4/CD8比值变化无显著差异(0.30 vs 0.32,P=.854)。

核心结论

  • 在晚期HIV疾病开始ART的患者中,针对肠相关淋巴组织和微生物群的营养干预未增强ART明确的免疫学获益。

研究设计与样本

  • 先导性多中心随机、安慰剂对照、双盲研究,78例未治疗且CD4 T细胞<350个/μL或艾滋病的HIV感染者随机接受每日PMT25341或安慰剂48周,均联合一线ART。

主要发现

  • 59例完成随访,平均CD4+ T细胞计数221 ± 108 cells/μL,平均CD4/CD8比值0.26 ± 0.19。
  • PMT25341耐受良好,无归因于干预的3-4级不良事件。
  • PMT25341组与安慰剂组CD4+ T细胞计数平均变化无显著差异(278 vs 250 cells/μL,P=.474)。
  • PMT25341组与安慰剂组CD4/CD8比值变化无显著差异(0.30 vs 0.32,P=.854)。
  • 次要终点在治疗组间未检测到差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)-infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear. METHODS: This was a pilot multicenter randomized, placebo-controlled, double-blind study in which 78 HIV-infected, ART-naive subjects with <350 CD4 T cells/μL or AIDS were randomized to either daily PMT25341 (a mixture of synbiotics, omega-3/6 fatty acids and amino acids) or placebo for 48 weeks, each in combination with first-line ART. Primary endpoints were changes in CD4 T-cell counts and CD4/CD8 ratio from baseline to week 48 and safety. Secondary endpoints were changes in markers of T-cell activation, bacterial translocation, inflammation, and α and β microbiota diversity. RESULTS: Fifty-nine participants completed the follow-up with a mean CD4+ T-cell count of 221 ± 108 cells/μL and mean CD4/CD8 ratio of 0.26 ± 0.19. PMT25341 was well tolerated, without grade 3-4 adverse effects attributable to the intervention. While most of the assessed biomarkers improved during the follow-up in both arms, PMT25341-treated subjects did not experience any significant change, compared to placebo-treated subjects, in mean CD4+ T-cell count change (278 vs 250 cells/μL, P = .474) or CD4/CD8 ratio change (0.30 vs 0.32, P = .854). Similarly, we did not detect differences between treatment arms in secondary endpoints. CONCLUSIONS: In HIV-infected patients initiating ART at advanced disease, the clear immunological benefits of ART were not enhanced by this nutritional intervention targeting the gut-associated lymphoid tissue and microbiota. CLINICAL TRIALS REGISTRATION: NCT00870363.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Serrano-Villar S, de Lagarde M, Vázquez-Castellanos J, et al. Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study). Clin Infect Dis. 2019. PMID: 29788075. doi:10.1093/cid/ciy414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。